secwatch.observer — SEC 8-K summary
======================================

Issuer:     Voyager Therapeutics, Inc. (VYGR)
CIK:        0001640266
Form:       8-K
Filed at:   2023-11-06T23:59:59+00:00
Accession:  0001558370-23-017753
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Voyager Q3 net loss $25.9M; advances VY-TAU01 IND, SOD1 ALS candidate selection by year-end
--------------------------------------------------------------------------------

- Net loss $25.9M in Q3 2023 vs net income $17.6M in Q3 2022; collaboration revenue fell to $4.6M from $41.1M.
- Cash, equivalents and marketable securities $252.9M as of Sep 30, 2023; runway expected into mid-2025.
- Initiated GLP tox for anti-tau antibody VY-TAU01; IND filing expected H1 2024 for Alzheimer's disease.
- SOD1 ALS gene therapy program on track for development candidate selection in 2023, IND target mid-2025.
- License of TRACER capsid from Pfizer to Alexion/AstraZeneca Rare Disease assigned; terms unchanged.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1640266/000155837023017753/0001558370-23-017753-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1640266/000155837023017753/vygr-20231106x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-017753

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer